Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies Ltd., says that the “Mirror EffectTM” is a proprietary immunologic treatment that has finally been able to separate the beneficial graft versus tumor (GVT) response of an allogeneic bone marrow transplant (BMT) from the deadly graft versus host (GVHD) complication. The separation of the GVT and GVHD processes has been called the “Holy Grail” of cancer treatment.
Dr. Michael Har-Noy tells us that the answer was to design a T-cell infusion that would mimic the immunologic responses caused by the transplanted donor cells but that would be ultimately controlled by the patient's own immune cells. This proprietary response, termed the “Mirror EffectTM”, could theoretically produce the curative response of a BMT without the lethal complication of GVHD.
Dr. Michael Har-Noy says that the Mirror EffectTM process reverses the intimately related GVT and GVHD mechanisms that arise from the infused donor cells. This effect thus arises from the host immune response rather than from the transplanted cells, thus precipitating a host versus tumor (HVT) response that is associated with the non-toxic host versus graft (HVG) rejection process. To initiate the Mirror EffectTM reaction, T-cells from a normal donor are infused into a cancer patient. Dr. Michael Har-Noy says that these infused cells prompt the patient's immune response to attack the malignant cells (HVT effect) and create an extremely inflammatory environment which incapacitates the tumor's ability to evade the patient's immune response.
Dr. Michael Har-Noy says that since the HVT response must be linked to a HVG rejection mechanism, the patient needs have an intact immune system that can rise up and reject the donor T-cells. Additionally, since graft rejection (HVG) is the desired response, the donor cells are also ideally intentionally mismatched to the recipient. Dr. Michael Har-Noy says that this is a vital and much-needed advancement over allogeneic BMT treatments, where only one third of potential recipients have a suitably matched donor.
The Mirror EffectTM, notes Dr. Michael Har-Noy, therefore involves the infusion of intentionally mismatched donor cells into a cancer patient that has received no pretreatment. The infused cells are then rejected by the patient's immune system. This HVG rejection is the “mirror” of the deadly GVHD but has no toxicity. The HVG mechanism precipitates host-mediated tumor destruction (HVT), which is the “mirror” of the GVT process. Dr. Michael Har-Noy concludes that the Mirror EffectTM imitates the desired GVT effect of an allogeneic BMT while simultaneously avoiding the often-fatal toxicity of GVHD.
Dr. Michael Har-Noy feels that the Mirror EffectTM may be the beginning an entire new field of oncology. Please visit www.immunocare.net for more information on Dr. Michael Har-noy's ongoing clinical trials.